LMF Acquisition Opportunities Inc. Warrant

Company Overview

Business Model: SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on developing and commercializing transformational treatments for critically ill patients experiencing organ failure and potential loss of life. Its core product, the Selective Cytopheretic Device (SCD), is designed as a disease-modifying device that neutralizes over-active immune cells and halts the cytokine storm, thereby addressing destructive hyperinflammation. The company generates revenue primarily through the commercial sale of its pediatric SCD therapy, QUELIMMUNE, and aims to expand revenue generation through its adult SCD and potential future licensing or collaboration agreements.

Market Position: SeaStar Medical Holding Corporation holds a unique market position with QUELIMMUNE, which is the only FDA-approved product for pediatric patients with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy. The company's SCD therapy has been awarded six Breakthrough Device Designations (BDD) by the FDA across multiple therapeutic indications, including adult AKI, Cardiorenal Syndrome (CRS) awaiting left ventricular assist device (LVAD) implantation, hepatorenal syndrome, end-stage renal disease (ESRD), and systemic inflammatory response during cardiac surgery. These designations are expected to expedite clinical development and regulatory review. Clinical data from trials involving over 150 pediatric and adult AKI patients on CRRT demonstrated a 50% reduction in mortality rates, with no survivors requiring dialysis at 60 days.

Recent Strategic Developments:

• FDA Approval & Commercial Launch: Received FDA approval under a Humanitarian Device Exemption (HDE) for its pediatric SCD therapy (QUELIMMUNE) on February 21, 2024, and commenced first commercial shipments in July 2024.
• Clinical Trials: Actively conducting a pivotal clinical trial (NEUTRALIZE-AKI) to assess the safety and efficacy of SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy (CRRT). Also conducting a feasibility study of SCD therapy in adult patients with CRS awaiting LVAD implantation.
• Regulatory Milestones: In December 2025, the FDA approved a reduction in the mandatory enrollment size of the SAVE Surveillance Registry for QUELIMMUNE from 300 to 50 patients, with the 50th patient enrolled on March 4, 2026.
• Commercial Model Transition: Terminated a distribution agreement with Nuwellis in August 2024 and transitioned to a direct sales model for QUELIMMUNE in the U.S. market, building an internal sales and marketing infrastructure.

Geographic Footprint: SeaStar Medical Holding Corporation's primary operational regions and current sales focus are entirely within the United States. The company has no current plans to expand sales of QUELIMMUNE outside the U.S.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 95.7% (2025), 100.0% (2024)
• Operating Margin: -986.6% (2025), -13216.3% (2024)
• Net Margin: -984.6% (2025), -18392.6% (2024)

Investment in Growth:

• R&D Expenditure: $7.5 million (609.2% of revenue)
• Capital Expenditures: Not explicitly disclosed.
• Strategic Investments: Significant investment in ongoing clinical trials, including the NEUTRALIZE-AKI pivotal study for adult AKI, and feasibility studies for CRS and other indications. The company is also developing a next-generation SCD.

Business Segment Analysis

Device Segment

Financial Performance:

• Revenue: $1.2 million (+814.1% YoY)
• Operating Margin: -986.6%
• Key Growth Drivers: Increased adoption of QUELIMMUNE, with 10 active commercial hospital customers as of December 31, 2025, up from 3 in 2024. The increase is also attributable to a full year of sales activity in 2025 compared to six months in 2024.

Product Portfolio:

• Selective Cytopheretic Device (SCD) Platform: An extracorporeal synthetic membrane device designed to modulate inflammation by selectively binding and deactivating highly activated neutrophils and monocytes in a low ionized calcium environment.
• QUELIMMUNE: Pediatric SCD therapy, FDA-approved under HDE for critically ill pediatric patients with AKI due to sepsis or a septic condition requiring CRRT.
• Investigational SCD for Adults: Currently in a pivotal clinical trial (NEUTRALIZE-AKI) for adult AKI requiring CRRT. Also in feasibility studies for CRS awaiting LVAD implantation, and being explored for hepatorenal syndrome, ESRD, and systemic inflammatory response during cardiac surgery.

Market Dynamics:

• The company addresses a substantial clinical need for hyperinflammation control, targeting over one million patients annually facing life-threatening hyperinflammatory conditions.
• The U.S. AKI patient population is growing at an average of 6.9% per year, with hospital costs associated with AKI estimated between $5.4 billion and $20 billion annually.
• The pediatric AKI patient population on CRRT in the U.S. is estimated at less than 8,000 patients per year.
• Health economic outcomes research suggests QUELIMMUNE is cost-beneficial, projecting savings of approximately $40,000 per hospitalization by reducing mortality and hospital length of stay by 3 days in pediatric AKI patients requiring CKRT.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: None paid to date, and no dividends are anticipated in the foreseeable future.

Balance Sheet Position:

• Cash and Equivalents: $12.0 million (as of December 31, 2025)
• Total Debt: $0.5 million (notes payable, as of December 31, 2025)
• Net Cash Position: $11.5 million (as of December 31, 2025)
• Debt Maturity Profile: A $0.7 million insurance financing arrangement entered in October 2025 is to be paid in 10 monthly installments, with the final installment set for August 2026.

Cash Flow Generation:

• Operating Cash Flow: $(13.6) million (used in operating activities for the year ended December 31, 2025)
• Free Cash Flow: Not explicitly disclosed.

Operational Excellence

Production & Service Model: SeaStar Medical Holding Corporation outsources the manufacturing of component parts for its SCD, such as cartridges and tubing sets, and conducts the final assembly of its SCD clinical kits in-house. The company adheres to current Good Manufacturing Practice (cGMP) for both outsourced manufacturing and in-house assembly.

Supply Chain Architecture: Key Suppliers & Partners:

• Cartridges & Blood Tubing Sets: Fresenius USA Marketing, Inc. (FUSA), an affiliate of Fresenius Medical Care North America (FMCNA), is the current sole supplier for cartridges. The supply agreement with FUSA was extended through December 31, 2027.
• IV Solutions: The use of SCD in hospital settings requires the administration of regional citrate anticoagulation (RCA) and calcium replacement, both intravenous (IV) solutions, which have limited manufacturers/suppliers nationwide.
• Second Source Development: SeaStar Medical Holding Corporation is developing a second source for both adult and pediatric cartridges to mitigate potential supply disruptions.

Facility Network:

• Headquarters: Leased on a month-to-month basis at 3513 Brighton Blvd., Suite 410, Denver, CO 80216.
• Manufacturing/Assembly/Warehousing: A leased facility at 3513 Brighton Boulevard, Denver, CO 80216, is used for final assembly, warehousing, and fulfillment under an annual lease agreement.
• Research & Development: R&D activities are conducted internally and with the support of third-party contract research organizations and consultants.

Operational Metrics: Not explicitly disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Following the termination of a distribution agreement with a third party, SeaStar Medical Holding Corporation has adopted a direct sales model for QUELIMMUNE in the U.S. Pediatric Market, building an internal sales and marketing team.
• Channel Partners: Fresenius USA Marketing, Inc. (FUSA) holds a right of first refusal to be the exclusive distributor of the adult SCD products in the United States for three years after regulatory approval.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: As of December 31, 2025, the company had 10 active commercial hospital customers for QUELIMMUNE, an increase from 3 in 2024. The company targets top-tier pediatric medical facilities.
• Customer Concentration: Not explicitly disclosed.

Geographic Revenue Distribution:

• United States: 100% of total revenue for the years ended December 31, 2025, and 2024.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device industry for treating inflammation is highly competitive, characterized by significant capital and regulatory challenges. The demand for ICU renal replacement therapy is growing, with the CRRT global market estimated at $986 million ($354 million in the U.S.) as of 2019. The AKI patient population in the U.S. is growing at an average of 6.9% per year.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: SeaStar Medical Holding Corporation competes with numerous U.S. and foreign companies in the medical device industry. While Fresenius Medical Care Holdings, Inc. and Vantive, Inc. are major operators in the CRRT market, SeaStar Medical Holding Corporation is not aware of any similar device that has completed regulatory approval for the treatment of AKI requiring CRRT in adults or children.

Emerging Competitive Threats: The company faces potential threats from new scientific or technological developments and new treatment modalities that could be more efficacious or economical.

Competitive Response Strategy: The company's strategy includes innovating and expanding applications through clinical trials, differentiating its products through medical education, pursuing business development and out-licensing activities, and scaling production with manufacturing partners.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company operates in an intensely competitive medical device industry. Its products may become obsolete due to new scientific or technological developments or more efficacious/economical alternative treatments. Lack of third-party coverage and reimbursement for its devices could delay or limit adoption. Technology Disruption: The SCD relies on existing CRRT pump systems and regional citrate anticoagulation (RCA). Future developments in these areas could necessitate reconfiguring the SCD or render it obsolete.

Operational & Execution Risks

Supply Chain Vulnerabilities: The company relies on a single supplier (Fresenius USA Marketing, Inc.) for critical components like cartridges and blood tubing sets. There are also limited manufacturers/suppliers for IV solutions (RCA and calcium replacement) required for SCD use. Any disruptions could impact clinical trials and commercialization. Capacity Constraints: Difficulties in manufacturing the SCD could lead to delayed shipments or supply constraints, adversely affecting revenue and expenses.

Financial & Regulatory Risks

Market & Financial Risks: SeaStar Medical Holding Corporation has incurred significant losses since inception and has an accumulated deficit of $151.7 million as of December 31, 2025. There is substantial doubt about its ability to continue as a going concern, and it will require additional financing. The trading price of its Common Stock has been and is expected to remain volatile. Regulatory & Compliance Risks: The company faces challenges in obtaining additional FDA approvals for its adult SCD, and delays in clinical trials could jeopardize regulatory approval. It is subject to extensive government regulations (FDA, state, foreign) governing development, testing, manufacturing, and commercialization. Improper marketing or promotion of products could lead to enforcement actions. Stringent and changing privacy laws (e.g., CCPA) pose compliance risks.

Geopolitical & External Risks

Geopolitical Exposure: Conflicts, military actions, terrorist attacks, political events, public health crises, and changes in regulatory regimes or general instability could adversely affect business operations, suppliers, or customers.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: SeaStar Medical Holding Corporation's R&D is centered on its Selective Cytopheretic Device (SCD) platform. The SCD is designed to modulate inflammation by selectively binding and deactivating highly activated neutrophils and monocytes in a low ionized calcium environment, a mechanism that is organ agnostic and targets both acute and chronic inflammatory conditions. Innovation Pipeline: The company is actively pursuing clinical development for multiple indications, including adult AKI, Cardiorenal Syndrome (CRS), hepatorenal syndrome, end-stage renal disease (ESRD), and systemic inflammatory response while undergoing cardiac surgery. Preclinical studies have explored applications in acute myocardial infarction, intracranial hemorrhage, chronic heart failure, sepsis, and acute respiratory distress syndrome. The company also plans to develop a next-generation SCD.

Intellectual Property Portfolio:

• Patent Strategy: The company's patent portfolio consists of 46 issued patents and 1 pending patent application in the U.S. and certain foreign jurisdictions. Of these, 21 patents and 1 application are solely owned, and 25 patents are co-owned with the University of Michigan (UOM). Patents have terms expiring from 2025 through 2032.
• Licensing Programs: SeaStar Medical Holding Corporation holds an exclusive worldwide, royalty-bearing license from the University of Michigan for its interest in the co-owned patents and applications, covering human therapeutic indications. The license includes a 1% royalty on net sales and a $0.1 million milestone payment upon FDA approval of the first licensed product (paid in 2024).

Technology Partnerships: The University of Michigan is a key partner, co-owning patents and collaborating on exploratory clinical research to identify additional patient populations that may benefit from SCD therapy.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success depends on the continuing service of key employees, particularly its Chief Executive Officer, Eric Schlorff. The company will need to attract and retain highly skilled managerial, scientific, and administrative personnel to implement its business plan and growth strategies.

Board Composition: The Board of Directors includes Chairperson Jennifer A. Baird, and Directors John Neuman, Kenneth Van Heel, and Bernadette N. Vincent.

Human Capital Strategy

Workforce Composition:

• Total Employees: 17 full-time employees as of December 31, 2025.

Talent Management: Acquisition & Retention: The company's success is highly dependent on its ability to attract and retain qualified scientific, technical, and managerial personnel, given the specialized nature of its business and intense competition for such individuals.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: The SCD is classified as a Class III medical device, requiring either Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) approval from the FDA. The FDA's Center for Biological Evaluation and Research has primary jurisdiction. The company must comply with extensive FDA regulations governing development, testing, manufacturing, labeling, marketing, storage, distribution, advertising, promotion, and post-marketing surveillance. International Compliance: While the company is subject to comparable international regulatory agencies, it currently has no plans to expand sales of QUELIMMUNE outside the U.S.

Legal Proceedings:

• Class Action: On July 5, 2024, a putative class action complaint (Wells v. SeaStar Medical Holding Corporation et al.) was filed in the U.S. District Court for the District of Colorado, alleging material misstatements or omissions regarding FDA approval timing and financial statement restatement. A motion to dismiss was filed by the defendants, and a Magistrate Judge recommended dismissal with leave to amend on February 27, 2026.
• Derivative Action: On December 13, 2024, a putative stockholder derivative action (Lazo v. Schlorff et. al.) was filed in the U.S. District Court for the District of Colorado, with factual allegations substantially similar to the Class Action, including alleged breaches of fiduciary duties and deficiencies in internal financial controls. This action was stayed pending resolution of the Class Action's motion to dismiss.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: -0.03% for the year ended December 31, 2025, and 0.00% for the year ended December 31, 2024.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the company had federal NOL carryforwards of approximately $117.9 million and state NOL carryforwards of $52.5 million. Approximately $65.0 million of federal NOLs can be carried forward indefinitely, while the remaining $52.8 million begin expiring in 2027.
• Valuation Allowance: A full valuation allowance of $32.0 million as of December 31, 2025, and $28.5 million as of December 31, 2024, has been recorded against net deferred tax assets due to the uncertainty of future profitable operations.
• R&D Tax Credit Carryforwards: Federal R&D credit carryforwards were approximately $0.7 million as of December 31, 2025, and $0.5 million as of December 31, 2024, expiring starting in 2042.
• Energy Credit Carryforwards: Federal energy credit carryforwards were approximately $0.6 million as of December 31, 2025, and 2024, expiring starting in 2027.
• Geographic Tax Planning: The company files U.S. federal and state tax returns, with state NOLs in California, Florida, Illinois, and Virginia.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: SeaStar Medical Holding Corporation has obtained general clinical trial liability insurance coverage. In October 2025, the company entered into a financing arrangement to cover a portion of an annual insurance policy premium totaling $0.7 million.
• Risk Transfer Mechanisms: Not explicitly disclosed.